Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Rasmus Rojkjaer"'
Autor:
Brian Lauritzen, Dorthe Viuff, Pär I. Johansson, A.E. Pusateri, Søren Andersen, Rasmus Rojkjaer
Publikováno v:
BJA: British Journal of Anaesthesia
Background A range of plasma volume expanders is used clinically, often in settings where haemostasis may already be impaired. The haemostatic agent, recombinant activated factor VII (rFVIIa, NovoSeven®), may be used to improve haemostasis but poten
Autor:
Pär I. Johansson, José A Salado-Jimena, Mette S Svendsen, Rasmus Rojkjaer, Annemarie T. Kristensen, Marianne Kjalke
Publikováno v:
Transfusion. 47:2057-2065
BACKGROUND: The increasing demand for platelet (PLT) transfusions has focused attention on appropriate use. Coated PLTs are a subpopulation of highly procoagulant PLTs formed by simultaneous stimulation by the agonist's collagen and thrombin hypothes
Autor:
Laust Peter Gade, Rasmus Rojkjaer, Dorte Xenia Gram, Mads Kjelgaard-Hansen, Bo Wiinberg, Annemarie T. Kristensen, Pär I. Johansson, Asger Lundorff Jensen
Publikováno v:
The Veterinary Journal. 174:62-68
Thromboelastography (TEG) may be a valuable supplement to the coagulation assays activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT), fibrinogen, antithrombin (AT) and D-Dimer currently used in most clinical pathol
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:774-780
Summary. Background: Activation of platelets with a combination of collagen and thrombin generates a subpopulation of highly procoagulant ‘coated’ platelets characterized by high surface expression of fibrinogen and other procoagulant proteins. O
Autor:
Mads Kjelgaard-Hansen, Asger Lundorff Jensen, Bo Wiinberg, Annemarie T. Kristensen, Pär I. Johansson, Rasmus Rojkjaer
Publikováno v:
University of Copenhagen
Background Thromboelastography (TEG) is an analytical method that enables global assessment of hemostatic function in whole blood (WB) with evaluation of both plasma and cellular components of hemostasis. TEG has a largely unused potential in the dia
Autor:
Mikael Tranholm, Egon Persson, Annemarie T. Kristensen, Kim Kristensen, Rasmus Rojkjaer, Charles Pyke
Publikováno v:
University of Copenhagen
It is currently debated whether the mechanism of action of therapeutic doses of recombinant factor VIIa (rFVIIa, Novo-Seven) relies on the tissue factor (TF)-independent activity of the enzyme. The present study was conducted to investigate the in vi
Publikováno v:
Journal of Thrombosis and Haemostasis. 1:2175-2178
Summary. Background: Recombinant coagulation factor VIIa (rFVIIa) is generally accepted for treatment of patients with inhibitor-complicated hemophilia. Recently, rFVIIa variants with a specific enhancement of the tissue factor (TF)-independent prote
Publikováno v:
Blood. 91:516-528
The consequences of assembling the contact system of proteins on the surface of vascular cells has received little study. We asked whether assembly of these proteins on the surface of cultured human endothelial cells (HUVECs) results in the activatio
Publikováno v:
The journal of extra-corporeal technology. 41(2)
Recombinant factor VIIa (rFVIIa) interacts preferentially with coated platelets characterized by a high exposure of phosphatidyl serine (PS), FV, FVIII, FIX, and FX binding, and fibrinogen. Cardiopulmonary bypass (CPB) is known to impair platelet fun
Publikováno v:
Canadian Journal of Cardiology, 100(108). Elsevier Inc.
Background Human ‘new pressor protein' (NPP), related to coagulation beta-factor XIIa (β-FXIIa), potently releases sympathoadrenal catecholamines in bioassay rats, with concurrent elevation of systolic and diastolic blood pressure (SBP/DBP) and he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16f8235408d83a25b2fea603551bf16d
https://pure.eur.nl/en/publications/52f259a4-8716-4014-857e-7b9def55e538
https://pure.eur.nl/en/publications/52f259a4-8716-4014-857e-7b9def55e538